{
    "clinical_study": {
        "@rank": "28358", 
        "arm_group": [
            {
                "arm_group_label": "5mg/m2 DX-88  IV", 
                "arm_group_type": "Experimental", 
                "description": "5mg/m2 DX-88 (ecallantide)administered intravenously"
            }, 
            {
                "arm_group_label": "10mg/m2 DX-88 IV", 
                "arm_group_type": "Experimental", 
                "description": "10mg/m2 DX-88(ecallantide)administered intravenously"
            }, 
            {
                "arm_group_label": "20mg/m2 DX-88 IV", 
                "arm_group_type": "Experimental", 
                "description": "20mg/m2 DX-88 (ecallantide) administered intravenously"
            }, 
            {
                "arm_group_label": "30 mg DX-88 SC", 
                "arm_group_type": "Experimental", 
                "description": "30mg DX-88(ecallantide)administered subcutaneously"
            }
        ], 
        "brief_summary": {
            "textblock": "EDEMA2 is an open-label, Phase 2 dose-ranging study designed to assess the safety and\n      efficacy of repeated dosing of DX-88 (recombinant plasma kallikrein inhibitor) in Patients\n      with Hereditary Angioedema."
        }, 
        "brief_title": "EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema", 
        "completion_date": {
            "#text": "January 2006", 
            "@type": "Actual"
        }, 
        "condition": "Hereditary Angioedema (HAE)", 
        "condition_browse": {
            "mesh_term": [
                "Angioedema", 
                "Angioedemas, Hereditary"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  10 years of age or older\n\n          -  Documented diagnosis of HAE (Type I or II)\n\n          -  Patient reported to a study site no later than 4 hours following patient recognition\n             of the onset of the attack\n\n          -  Willing and able to give informed consent\n\n        Exclusion Criteria:\n\n          -  Patients with a serious intercurrent illness or serious active infection\n\n          -  Patient with serum creatinine greater than 110% the upper limit of normal or liver\n             transaminases 2 times the upper limit of normal\n\n          -  Receipt of an investigational drug or device, within 30 days prior to study treatment\n\n          -  Pregnancy or breastfeeding\n\n          -  Diagnosis of acquired angioedema (AAE)\n\n          -  Patients who had not completed their Day-7 follow-up procedures for a previously\n             treated attack"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "77", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 16, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01826916", 
            "org_study_id": "DX-88/5", 
            "secondary_id": "EDEMA2"
        }, 
        "intervention": {
            "arm_group_label": [
                "5mg/m2 DX-88  IV", 
                "10mg/m2 DX-88 IV", 
                "20mg/m2 DX-88 IV", 
                "30 mg DX-88 SC"
            ], 
            "description": "solution for injection 10 mg/mL", 
            "intervention_name": "DX-88 (ecallantide)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 4, 2013", 
        "number_of_arms": "4", 
        "official_title": "EDEMA2: An Open-Label Study to Assess the Efficacy and Tolerability of Repeated Doses of DX-88 (Recombinant Plasma Kallikrein Inhibitor) in Patients With Hereditary Angioedema", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "successful outcome is defined as attack resolution begun within 4 hrs after treatment and maintained for 24 hours", 
                "measure": "Proportion of attacks treated with successful outcome", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "partial response is defined as an initial response to dosing followed by a relapse within 4 to 24 hours", 
                "measure": "Proportion of attacks with a partial response", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01826916"
        }, 
        "responsible_party": {
            "name_title": "Bill Pullman, MD, PhD, Executive Vice President, Chief Development Officer", 
            "organization": "Dyax Corp."
        }, 
        "secondary_outcome": [
            {
                "measure": "Proportion of patients who respond to a 2nd dose of ecallantide after an initial, partial response", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "measure": "Time to resolution onset of each acute attack, as determined by patient report", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }
        ], 
        "source": "Dyax Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dyax Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2003", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}